Reagentes e instrumentos para imunologia, biologia celular e biologia molecular.

Kinetin riboside [4338-47-0]

Imprimir

Referência HY-101055-50mg

Tamanho : 50mg

Marca : MedChemExpress

Solicitar mais informações

Description

Kinetin riboside, a cytokinin analog, can induce apoptosis in cancer cells. It inhibits the proliferation of HCT-15 cells with an IC₅₀ of 2.5 μM.

IC₅₀ & Target

IC50: 2.5 μM (HCT-15 cells)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	0.16 μM Compound: 1; KR	Antiproliferative activity against human A-375 cells assessed as cell growth inhibition incubated for 72 hrs by Beckman Coulter counting method Antiproliferative activity against human A-375 cells assessed as cell growth inhibition incubated for 72 hrs by Beckman Coulter counting method	[PMID: 38280656]
A549	IC₅₀	10.5 μM Compound: 1; KR	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 38280656]
B16	IC₅₀	0.2 μM Compound: 1; KR	Cytotoxicity against mouse B16 cells assessed as inhibition of cell growth incubated for 10 days by crystal violet staining based assay Cytotoxicity against mouse B16 cells assessed as inhibition of cell growth incubated for 10 days by crystal violet staining based assay	[PMID: 38280656]
CCRF-CEM	IC₅₀	1.6 μM Compound: 1; KR	Antiproliferative activity against human CEM cells assessed as cell growth inhibition incubated for 72 hrs by Calcein AM staining based fluorescence assay Antiproliferative activity against human CEM cells assessed as cell growth inhibition incubated for 72 hrs by Calcein AM staining based fluorescence assay	[PMID: 38280656]
Caco-2	GI₅₀	45.6 μM Compound: 20, FMA	Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay	[PMID: 18588281]
Caco-2	IC₅₀	23.5 μM Compound: 1; KR	Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38280656]
Caco-2	IC₅₀	42 μM Compound: 1; KR	Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38280656]
Caco-2	IC₅₀	88 μM Compound: 1; KR	Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38280656]
G-361	IC₅₀	0.16 μM Compound: 1; KR	Antiproliferative activity against human G361 cells assessed as cell growth inhibition incubated for 72 hrs by Beckman Coulter counting method Antiproliferative activity against human G361 cells assessed as cell growth inhibition incubated for 72 hrs by Beckman Coulter counting method	[PMID: 38280656]
HCT-116	IC₅₀	0.16 μM Compound: 1; KR	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by Beckman Coulter counting method Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by Beckman Coulter counting method	[PMID: 38280656]
HCT-15	IC₅₀	12.3 μM Compound: 1; KR	Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition incubated for 4 days by SRB assay Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition incubated for 4 days by SRB assay	[PMID: 38280656]
HL-60	IC₅₀	0.8 μM Compound: 1; KR	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by Calcein AM staining based fluorescence assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by Calcein AM staining based fluorescence assay	[PMID: 38280656]
HL-60	IC₅₀	0.98 μM Compound: 1; KR	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth incubated for 5 days Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth incubated for 5 days	[PMID: 38280656]
HS27	IC₅₀	0.18 μM Compound: 1; KR	Antiproliferative activity against human HS27 cells assessed as cell growth inhibition incubated for 72 hrs by Beckman Coulter counting method Antiproliferative activity against human HS27 cells assessed as cell growth inhibition incubated for 72 hrs by Beckman Coulter counting method	[PMID: 38280656]
HT-29	GI₅₀	60.2 μM Compound: 20, FMA	Antitumor activity against human HT29 cells after 48 hrs by MTS assay Antitumor activity against human HT29 cells after 48 hrs by MTS assay	[PMID: 18588281]
HT-29	IC₅₀	0.16 μM Compound: 1; KR	Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 72 hrs by Beckman Coulter counting method Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 72 hrs by Beckman Coulter counting method	[PMID: 38280656]
HeLa	IC₅₀	4.3 μM Compound: 1; KR	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by Calcein AM staining based fluorescence assay Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by Calcein AM staining based fluorescence assay	[PMID: 38280656]
HeLa	IC₅₀	> 100 μM Compound: 1; KR	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38280656]
HeLa	IC₅₀	> 100 μM Compound: 1; KR	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38280656]
HeLa	IC₅₀	> 100 μM Compound: 1; KR	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38280656]
K562	GI₅₀	3.3 μM Compound: 20, FMA	Antitumor activity against human K562 cells after 48 hrs by MTS assay Antitumor activity against human K562 cells after 48 hrs by MTS assay	[PMID: 18588281]
LOX IMVI	IC₅₀	0.16 μM Compound: 1; KR	Antiproliferative activity against human LOX IMVI cells assessed as cell growth inhibition incubated for 72 hrs by Beckman Coulter counting method Antiproliferative activity against human LOX IMVI cells assessed as cell growth inhibition incubated for 72 hrs by Beckman Coulter counting method	[PMID: 38280656]
MCF7	GI₅₀	45.6 μM Compound: 20, FMA	Antitumor activity against human MCF7 cells after 48 hrs by MTS assay Antitumor activity against human MCF7 cells after 48 hrs by MTS assay	[PMID: 18588281]
MCF7	IC₅₀	16.1 μM Compound: 1; KR	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38280656]
MCF7	IC₅₀	2.7 μM Compound: 1; KR	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38280656]
MCF7	IC₅₀	2.8 μM Compound: 1; KR	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38280656]
MCF7	IC₅₀	4.3 μM Compound: 1; KR	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by Calcein AM staining based fluorescence assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by Calcein AM staining based fluorescence assay	[PMID: 38280656]
MIA PaCa-2	IC₅₀	0.16 μM Compound: 1; KR	Antiproliferative activity against human MIA PaCa-2 cells assessed as cell growth inhibition incubated for 72 hrs by Beckman Coulter counting method Antiproliferative activity against human MIA PaCa-2 cells assessed as cell growth inhibition incubated for 72 hrs by Beckman Coulter counting method	[PMID: 38280656]
MIA PaCa-2	IC₅₀	2.6 μM Compound: 1; KR	Cytotoxicity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38280656]
MIA PaCa-2	IC₅₀	3.1 μM Compound: 1; KR	Cytotoxicity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38280656]
MIA PaCa-2	IC₅₀	> 100 μM Compound: 1; KR	Cytotoxicity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38280656]
MRC5	IC₅₀	1.7 μM Compound: 1; KR	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38280656]
MRC5	IC₅₀	18 μM Compound: 1; KR	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38280656]
MRC5	IC₅₀	2.5 μM Compound: 1; KR	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38280656]
OVCAR-3	IC₅₀	3.1 μM Compound: 1; KR	Cytotoxicity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38280656]
OVCAR-3	IC₅₀	7.8 μM Compound: 1; KR	Cytotoxicity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38280656]
OVCAR-3	IC₅₀	> 100 μM Compound: 1; KR	Cytotoxicity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 38280656]
Platelet	IC₅₀	41.16 μM Compound: 2c	Inhibition of collagen-induced human platelet aggregation after 3 mins by light transmission aggregometry Inhibition of collagen-induced human platelet aggregation after 3 mins by light transmission aggregometry	[PMID: 25467153]
RD	CC₅₀	7.8 μM Compound: 26	Cytotoxicity against human RD cells Cytotoxicity against human RD cells	[PMID: 26854380]
RD	EC₅₀	1.4 μM Compound: 26	Antiviral activity against Enterovirus 71 infected in human RD cells assessed as cell viability after 3 days by MTS assay Antiviral activity against Enterovirus 71 infected in human RD cells assessed as cell viability after 3 days by MTS assay	[PMID: 26854380]

In Vitro

Kinetin riboside displays antiproliferative and apoptogenic activity against various human cancer cell lines. Kinetin riboside is able to inhibit the proliferation in HCT-15 human colon cancer cells in a dose-dependent manner (IC₅₀=2.5 μM)^[1]. Kinetin riboside induces apoptosis in HeLa and mouse melanoma B16F-10 cells. Kinetin riboside disrupts the mitochondrial membrane potential and induces the release of cytochrome c and activation of caspase-3. Bad are up-regulated while Bcl-2 is down-regulated under kinetin riboside exposure^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Solvant et solubilité

In Vitro:

DMSO : 250 mg/mL (719.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8791 mL	14.3955 mL	28.7911 mL
5 mM	0.5758 mL	2.8791 mL	5.7582 mL
10 mM	0.2879 mL	1.4396 mL	2.8791 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Pureté et documentation

Purity: 99.88%

Fiche technique (279 KB) SDS (254 KB)

COA (253 KB) LCMS (93 KB)

Instruction de manipulation (2659 KB)

Références

[1]. Rajabi M, et al. Antiproliferative activity of kinetin riboside on HCT-15 colon cancer cell line. Nucleosides Nucleotides Nucleic Acids. 2012;31(6):474-81. [Content Brief]

[2]. Choi BH, et al. Kinetin riboside preferentially induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells. Cancer Lett. 2008 Mar 8;261(1):37-45. [Content Brief]

Kinetin riboside [4338-47-0]

Referência HY-101055-50mg

Marca : MedChemExpress

Kinetin riboside Related Antibodies